Experimental pill aims to rev up immune system against Hard-to-Treat tumors

NCT ID NCT05270213

Recruiting now Disease control Sponsor: Riboscience, LLC. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental drug called RBS2418, taken as a pill, to see if it can help the immune system fight advanced cancers that have spread or come back. The study involves 164 adults with various solid tumors who have already tried standard treatments. Some participants will receive RBS2418 alone, while others will get it combined with the immunotherapy drug pembrolizumab or other standard cancer therapies. The main goals are to check safety, find the best dose, and look for early signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

RBS2418 (an experimental immune modulator pill) and pembrolizumab (an immunotherapy drug)

What this could lead to

If successful, this could point toward a new treatment option for people with advanced cancers that have stopped responding to standard therapies.

What could go wrong

This is a very early Phase 1 trial with only 164 participants, so it is primarily testing safety and dosing. It may not lead to an effective treatment, and side effects are unknown.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

American Oncology Partners of Maryland
RECRUITING

Bethesda, Maryland, 20817, United States

Contact Email: •••••@•••••
Carolina BioOncology Institute
COMPLETED

Huntersville, North Carolina, 28078, United States
Christiana Care Health Services
RECRUITING

Newark, Delaware, 19713, United States

Contact Email: •••••@•••••
Honor Health Research Institute
RECRUITING

Scottsdale, Arizona, 85258, United States

Contact Email: •••••@•••••
Ichan School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States

Contact Email: •••••@•••••
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
RECRUITING

Baltimore, Maryland, 21224, United States

Contact Email: •••••@•••••
NEXT Virigina
RECRUITING

Fairfax, Virginia, 22031, United States

Contact Email: •••••@•••••
Norton Cancer Institute
RECRUITING

Louisville, Kentucky, 40202, United States

Contact Email: •••••@•••••
Ochsner Clinic Foundation
RECRUITING

New Orleans, Louisiana, 70121, United States

Contact Email: •••••@•••••
Stanford Cancer Institute
RECRUITING

Palo Alto, California, 94305, United States

Contact Email: •••••@•••••
Tranquil Research
WITHDRAWN

Webster, Texas, 77598, United States
UCLA Hematology/Oncology - Santa Monica
RECRUITING

Santa Monica, California, 90404, United States

Contact Email: •••••@•••••
University of Arizona
RECRUITING

Tucson, Arizona, 85724, United States

Contact Email: •••••@•••••
Vanderbilt-Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37235, United States

Contact Email: •••••@•••••